TR201905548T4 - Kanser kök hücresi hedefli ve ilaç dirençli kanser terapisi. - Google Patents
Kanser kök hücresi hedefli ve ilaç dirençli kanser terapisi. Download PDFInfo
- Publication number
- TR201905548T4 TR201905548T4 TR2019/05548T TR201905548T TR201905548T4 TR 201905548 T4 TR201905548 T4 TR 201905548T4 TR 2019/05548 T TR2019/05548 T TR 2019/05548T TR 201905548 T TR201905548 T TR 201905548T TR 201905548 T4 TR201905548 T4 TR 201905548T4
- Authority
- TR
- Turkey
- Prior art keywords
- drug resistant
- stem cell
- cell targeted
- cancer
- cancer stem
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 title abstract 2
- 210000000130 stem cell Anatomy 0.000 title abstract 2
- 238000011275 oncology therapy Methods 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- PTLRDCMBXHILCL-UHFFFAOYSA-M sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Mevcut buluş kanser hücrelerini tedavi etmek, azaltmak ya da elimine etmek için farmasötik kompozisyonlar sağlamaktadır; daha özel olarak mevcut buluş kanser kök hücreleri ve ilaç dirençli kanser hücrelerinin azaltılması ya da elimine edilmesi için sodyum meta arsenit rejiminin terapötik olarak etkili bir miktarını sağlamaktadır.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24118009P | 2009-09-10 | 2009-09-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201905548T4 true TR201905548T4 (tr) | 2019-05-21 |
Family
ID=43647965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/05548T TR201905548T4 (tr) | 2009-09-10 | 2010-09-09 | Kanser kök hücresi hedefli ve ilaç dirençli kanser terapisi. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20110059186A1 (tr) |
| EP (1) | EP2475362B1 (tr) |
| JP (1) | JP5710619B2 (tr) |
| KR (2) | KR20120061908A (tr) |
| CN (2) | CN107412771A (tr) |
| AR (1) | AR079000A1 (tr) |
| AU (1) | AU2010292192B2 (tr) |
| BR (1) | BR112012008315B1 (tr) |
| CA (1) | CA2772411C (tr) |
| CY (1) | CY1121973T1 (tr) |
| DK (1) | DK2475362T3 (tr) |
| ES (1) | ES2723778T3 (tr) |
| HU (1) | HUE043387T2 (tr) |
| IN (1) | IN2012DN02008A (tr) |
| LT (1) | LT2475362T (tr) |
| MX (1) | MX2012002855A (tr) |
| PL (1) | PL2475362T3 (tr) |
| PT (1) | PT2475362T (tr) |
| RU (1) | RU2568834C2 (tr) |
| SG (2) | SG179069A1 (tr) |
| SI (1) | SI2475362T1 (tr) |
| TR (1) | TR201905548T4 (tr) |
| TW (1) | TWI564012B (tr) |
| WO (1) | WO2011031890A2 (tr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1721615A1 (en) | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
| WO2012131487A2 (en) * | 2011-03-30 | 2012-10-04 | Kominox, Inc. | Compositions and methods for the treatment of cancer |
| WO2015046783A1 (en) | 2013-09-30 | 2015-04-02 | Korea Institute Of Radiological & Medical Sciences | Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising hrp-3 inhibitor |
| US20180036331A1 (en) * | 2016-03-24 | 2018-02-08 | The Board Of Regents Of The University Of Texas System | Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds |
| WO2018217975A1 (en) * | 2017-05-24 | 2018-11-29 | The Regents Of The University Of California | Antisense therapies for treating cancer |
| TWI749414B (zh) * | 2019-11-29 | 2021-12-11 | 高雄醫學大學 | 細胞學抹片影像自動分析及診察結果自動批改方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5441050A (en) | 1992-12-18 | 1995-08-15 | Neoprobe Corporation | Radiation responsive surgical instrument |
| US5889048A (en) * | 1994-02-18 | 1999-03-30 | Vorobieva; Tamara Vasilievna | Methods and compositions for treating defective cell functions |
| US5362735A (en) * | 1994-02-23 | 1994-11-08 | Smithkline Beecham Corporation | Rapamycin derivatives |
| AU751932B2 (en) * | 1997-10-15 | 2002-08-29 | Polarx Biopharmaceuticals, Inc. | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| EP1964557B1 (en) * | 1997-11-10 | 2013-01-02 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations |
| CN1233476A (zh) * | 1998-04-24 | 1999-11-03 | 陆道培 | 治疗急性白血病的药物及其制备方法 |
| US6262070B1 (en) * | 1998-11-04 | 2001-07-17 | Darwin Discovery Ltd. | Heterocyclic compounds and their therapeutic use |
| TW200408407A (en) * | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
| WO2003086424A1 (en) * | 2002-04-10 | 2003-10-23 | Korea Microbiological Laboratories, Ltd. | Pharmaceutical composition comprising arsenite for the treatment of malignancy |
| WO2006104292A1 (en) * | 2005-03-31 | 2006-10-05 | Komipharm International Co., Ltd. | Pharmaceutical composition comprising arsenic acid, meta-arsenite, and pharmaceutically acceptable salts |
| EP1721615A1 (en) * | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
| US20060292243A1 (en) * | 2005-06-24 | 2006-12-28 | Shao-Chi Hsin | Arsenic compounds for the treatment of the arsenic-sensitive blast-cell related diseases |
| US8945505B2 (en) * | 2007-02-02 | 2015-02-03 | Panaphix, Inc. | Use of arsenic compounds for treatment of pain and inflammation |
| US20080279961A1 (en) * | 2007-05-11 | 2008-11-13 | Burger Angelika M | Telomere targeting agents as stem cells directed treatments |
| US20090246291A1 (en) * | 2008-03-27 | 2009-10-01 | Angelika Burger | Method and compositions for treatment of cancer |
| IN2012DN02195A (tr) * | 2009-09-18 | 2015-08-21 | Kominox Inc |
-
2010
- 2010-09-09 TR TR2019/05548T patent/TR201905548T4/tr unknown
- 2010-09-09 WO PCT/US2010/048308 patent/WO2011031890A2/en active Application Filing
- 2010-09-09 KR KR1020127007326A patent/KR20120061908A/ko active Application Filing
- 2010-09-09 CN CN201610829065.6A patent/CN107412771A/zh active Pending
- 2010-09-09 PT PT10816100T patent/PT2475362T/pt unknown
- 2010-09-09 AU AU2010292192A patent/AU2010292192B2/en active Active
- 2010-09-09 SG SG2012016747A patent/SG179069A1/en unknown
- 2010-09-09 BR BR112012008315-5A patent/BR112012008315B1/pt active IP Right Grant
- 2010-09-09 MX MX2012002855A patent/MX2012002855A/es active IP Right Grant
- 2010-09-09 PL PL10816100T patent/PL2475362T3/pl unknown
- 2010-09-09 CA CA2772411A patent/CA2772411C/en active Active
- 2010-09-09 SG SG10201608967WA patent/SG10201608967WA/en unknown
- 2010-09-09 EP EP10816100.1A patent/EP2475362B1/en active Active
- 2010-09-09 LT LTEP10816100.1T patent/LT2475362T/lt unknown
- 2010-09-09 SI SI201031884T patent/SI2475362T1/sl unknown
- 2010-09-09 ES ES10816100T patent/ES2723778T3/es active Active
- 2010-09-09 KR KR1020157007013A patent/KR101721009B1/ko active IP Right Grant
- 2010-09-09 DK DK10816100.1T patent/DK2475362T3/da active
- 2010-09-09 HU HUE10816100A patent/HUE043387T2/hu unknown
- 2010-09-09 JP JP2012528903A patent/JP5710619B2/ja active Active
- 2010-09-09 CN CN201080040472XA patent/CN102753164A/zh active Pending
- 2010-09-09 RU RU2012108144/15A patent/RU2568834C2/ru active
- 2010-09-10 TW TW099130698A patent/TWI564012B/zh active
- 2010-09-10 US US12/879,347 patent/US20110059186A1/en not_active Abandoned
- 2010-09-10 AR ARP100103325A patent/AR079000A1/es not_active Application Discontinuation
-
2012
- 2012-03-06 IN IN2008DEN2012 patent/IN2012DN02008A/en unknown
-
2019
- 2019-04-23 CY CY20191100443T patent/CY1121973T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550450A1 (en) | Certain chemical entities, compositions and methods | |
| IN2012DN02805A (tr) | ||
| PH12015502362A1 (en) | Certain chemical entities, compositions and methods | |
| UA118248C2 (uk) | Інгібітори глюкозилцерамідсинтази | |
| EP2493464A4 (en) | METHYLSULFONYLMETHANE (MSM) FOR THE TREATMENT OF DRUG-RESISTANT MICROORGANISMS | |
| EA201300860A1 (ru) | Кристаллические трипептидные ингибиторы эпоксикетон-протеазы | |
| MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
| NZ706296A (en) | Glucosylceramide synthase inhibitors | |
| TR201905548T4 (tr) | Kanser kök hücresi hedefli ve ilaç dirençli kanser terapisi. | |
| GB201118656D0 (en) | New compounds | |
| GEP20156229B (en) | 5-alkynyl-pyrimidines | |
| IN2012DN01961A (tr) | ||
| MX2016003486A (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
| IN2012DN02471A (tr) | ||
| UA107204C2 (uk) | Протигрибкова композиція, що містить грибковий організм pythium oligandrum | |
| BR112012016543A2 (pt) | Tratamento com vb-201 | |
| GEP201606514B (en) | Apoptosis inhibitors and usage thereof | |
| PH12016500136A1 (en) | Positive allosteric modulators of nicotinic acetylcholine receptor | |
| MX2012013879A (es) | Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas. | |
| BR112012015677A2 (pt) | Compostos farmacêuticos. | |
| MX2011008994A (es) | Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2. | |
| EA201171414A1 (ru) | Ингибиторы белков семейства iap | |
| TR200900879A2 (tr) | Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler | |
| MD20140001A2 (ro) | Modulatori alosterici pozitivi ai receptorului nicotinic al acetilcolinei | |
| MX2012001797A (es) | Inhibidores de catepsina c. |